Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and clinical benefit study of droxidopa with randomized placebo-withdrawal in symptomatic neurogenic orthostatic hypotension
2007-005701-22Phase 3Completed
- Sponsor
- Chelsea Therapeutics International, Ltd.
- Start
- Aug 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Neurogenic Orthostatic Hypotension (nOH) comparing Droxidopa continuation with Placebo withdrawal (2 arms). Primary endpoint: Long-term safety. Started Aug 2008; status: completed.
02
Drugs
droxidopa
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on 2007-005701-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005701-22.